Avadel Pharmaceuticals will host a conference call on January 8, 2025, to discuss financial results and corporate updates.
Quiver AI Summary
Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast on January 8, 2025, at 4:30 p.m. ET to provide a corporate update and discuss its preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. Interested participants can access the live audio via the investor relations section of the company's website and are encouraged to register at least 10 minutes prior to the call. The company, known for its innovative biopharmaceutical solutions, recently gained FDA approval for LUMRYZ™, the first once-at-bedtime oxybate medication for treating cataplexy and excessive daytime sleepiness in patients with narcolepsy aged 7 years and older. A replay of the webcast will be available on the company's website for 90 days following the event.
Potential Positives
- Avadel Pharmaceuticals will provide a corporate update and discuss preliminary financial results, indicating transparency and engagement with investors.
- The scheduled conference call demonstrates the company's commitment to keeping stakeholders informed about its financial performance and business developments.
- Avadel's commercial product, LUMRYZ™, is highlighted as the first and only once-at-bedtime oxybate approved by the FDA for narcolepsy, showcasing a significant competitive edge in the market.
Potential Negatives
- Lack of specific financial information may raise concerns about performance transparency, potentially leading to investor skepticism during the upcoming conference call.
- The scheduled call for preliminary financial results suggests that detailed outcomes may not meet investor expectations, as preliminary reports often indicate uncertainty.
- The reliance on a single product, LUMRYZ™, poses a significant risk if future sales do not meet projections or if competitive pressures arise in the market.
FAQ
When will Avadel Pharmaceuticals host its conference call?
Avadel Pharmaceuticals will host its conference call on Wednesday, January 8, 2025, at 4:30 p.m. ET.
How can I access the live webcast of the conference call?
The live audio webcast can be accessed via the investor relations section of Avadel's website at www.avadel.com.
What financial results will Avadel discuss in the call?
Avadel will discuss its preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Will a replay of the conference call be available?
Yes, a replay of the webcast will be archived on Avadel’s website for 90 days following the event.
What is LUMRYZ™ and its significance?
LUMRYZ™ is Avadel’s FDA-approved treatment for narcolepsy, being the first once-at-bedtime oxybate for related symptoms.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVDL Insider Trading Activity
$AVDL insiders have traded $AVDL stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AVDL stock by insiders over the last 6 months:
- THOMAS S MCHUGH (Chief Financial Officer) has traded it 2 times. They made 2 purchases, buying 7,300 shares and 0 sales.
- GEOFFREY MICHAEL GLASS has traded it 2 times. They made 2 purchases, buying 20,279 shares and 0 sales.
- GREGORY J DIVIS (Chief Executive Officer) has traded it 2 times. They made 2 purchases, buying 10,000 shares and 0 sales.
- LINDA PALCZUK purchased 3,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AVDL Hedge Fund Activity
We have seen 100 institutional investors add shares of $AVDL stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIVO CAPITAL, LLC added 2,684,109 shares (+inf%) to their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC added 1,859,968 shares (+inf%) to their portfolio in Q3 2024
- POLAR CAPITAL HOLDINGS PLC removed 1,726,387 shares (-26.3%) from their portfolio in Q3 2024
- TRI LOCUM PARTNERS LP added 1,660,955 shares (+inf%) to their portfolio in Q3 2024
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 994,738 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 964,257 shares (+7007.2%) to their portfolio in Q3 2024
- PENN CAPITAL MANAGEMENT COMPANY, LLC added 608,399 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com . A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
[email protected]
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
[email protected]
(609) 273-3162
